Core Viewpoint - Shenlian Bio (688098.SH) has experienced a significant stock price increase, reaching a new high since March 2021, with a price of 15.4 yuan and a third consecutive day of a 20% limit up [1] Group 1: Stock Performance - The stock has hit a 20% limit up for three consecutive days, indicating strong market interest and investor confidence [1] - The current stock price of 15.4 yuan marks the highest level since March 2021 [1] Group 2: Company Operations - Shenlian Bio announced that there are no undisclosed significant matters as of the announcement date, confirming normal production and operations [1] - The company’s main business focuses on veterinary biological products, while its innovative drug pipeline, including AIDS monoclonal antibodies, is independently operated by its joint venture, Yangzhou Shizhiyuan Biotechnology Co., Ltd. [1] - The innovative drug business is characterized by long R&D cycles, high investment, and significant research risks [1]

Group 1 - The company's stock price has experienced an abnormal fluctuation, with a cumulative increase of over 30% in closing prices over three consecutive trading days [1] - The main business of the company is focused on veterinary biological products, while the innovative drug pipeline, including HIV monoclonal antibodies, is independently operated by its joint venture, Yangzhou Shizhi Source Biotechnology Co., Ltd. [1] - The related business has characteristics of long research and development cycles, high investment, and significant research risks [1]

Group 1 - The company's stock price has experienced an abnormal fluctuation, with a cumulative increase of over 30% in closing prices over three consecutive trading days [1] - The main business of the company is focused on veterinary biological products, while the innovative drug pipeline, including HIV monoclonal antibodies, is independently operated by its joint venture, Yangzhou Shizhi Source Biotechnology Co., Ltd. [1] - The related business has characteristics of long research and development cycles, high investment, and significant research risks [1]

Group 1 - The core business of the company is veterinary biological products, while the innovative drug pipeline, including AIDS monoclonal antibodies, is independently operated by its joint venture, Yangzhou Shizhi Source Biotechnology Co., Ltd. [2] - The related business has characteristics of long research and development cycles, high investment, and significant research risks [2]

Group 1 - The company, Shenlian Bio, has issued a notice regarding its business operations, which primarily focus on veterinary biological products [2] - The innovative drug pipeline, including monoclonal antibodies for HIV, is independently operated by its joint venture, Yangzhou Shizhiyuan Biotechnology Co., Ltd [2] - The related business is characterized by long research and development cycles, significant investment, and high research risks [2]